Pieris AG and The Sanofi Group have expanded their discovery and development partnership to include a novel multi-specific Anticalin program. The new program entitles Pieris to an upfront payment and committed research funding, as well as research, preclinical, regulatory and commercial milestones. Financial terms were not disclosed.   “Following more than two years of successful collaboration in this multi-program agreement, the expansion demonstrates that the Anticalin technology can deliver k...